Skip to content

Trans-coronary Cooling and Dilution for Cardioprotection During Revascularisation for ST-elevation Myocardial Infarction

Trans-coronary Cooling and Dilution for Cardioprotection During Revascularisation for ST-elevation Myocardial Infarction

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06128993
Acronym
STEMI-Cool
Enrollment
60
Registered
2023-11-13
Start date
2023-11-01
Completion date
2026-01-31
Last updated
2025-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction, Reperfusion Injury, Myocardial

Brief summary

A heart attack (myocardial infarction) occurs when an artery supplying blood to the heart is suddenly blocked resulting in damage to the heart muscle. Patients presenting to hospital with a heart attack undergo an immediate angiogram (x-ray of the arteries in the heart) and are usually treated immediately with a balloon and stent to open their blocked artery. This procedure is called primary percutaneous coronary intervention (or primary PCI for short). An angiogram is a routine procedure that involves insertion of fine plastic tube (catheter) into either the groin or wrist under local anaesthetic. The tube is passed into the artery in the heart and X-ray pictures are taken to find out if the arteries are blocked. Blocked arteries can usually be opened by passing a small balloon into the artery, via the fine plastic tube followed by placement of a stent (a fine metal coil) into the artery to prevent it from blocking again. Although this treatment is very successful, it can result in damage to the heart muscle when the artery is opened. Cooling the entire body has been shown to reduce heart muscle damage during heart attacks in some patients but not in others; however, it is uncomfortable due to the shivering, expensive and can result in delays in opening the blocked artery. The investigators are conducting a series of research studies to find out if cooling the heart muscle directly through the catheter being used for the normal primary angioplasty treatment using room temperature may be effective in preserving heart muscle, without the shortcomings of entire body cooling. The investigators have already published an initial series of ten cases in which this treatment appeared to be feasible without causing significant clinical problems. The present study is a pilot study designed to assess the rate of patient recruitment and feasibility of this new treatment while exploring some detailed outcomes measuring the restoration of blood flow within the coronary artery at the end of the procedure. Ultimately if the present pilot study is successful, the investigators plan to go on to undertake a much larger randomised outcome study to determine definitively whether this treatment can help reduce heart attack size.

Detailed description

The study population will comprise 60 patients with ST-Elevation Myocardial Infarction (STEMI) presenting to Harefield Hospital undergoing primary percutaneous coronary intervention (PCI). The primary aim of this pilot trial is to investigate the recruitment rate feasibility and safety of undertaking a randomised trial of simple intracoronary coronary cooling and dilution through the guiding catheter during primary PCI for STEMI to reduce myocardial infarction size. The secondary aims are as follows: 1. The study will explore the invasive haemodynamic assessment of coronary flow and microvascular function 2. The study will explore blood biomarkers before and after treatment for myocardial infarction 3. The study will explore myocardial salvage after treatment for myocardial infarction with magnetic resonance imaging (MRI) and subsequent final infarct size. Patients will be randomised 1:1 in the catheterisation lab when coronary angiography has demonstrated a target lesion with proposed primary PCI. Patients randomised to the intervention will receive transcatheter cooling and dilution in addition to usual clinical care. Patients randomised to control will receive usual care alone. A combined thermistor and pressure wire Coroventis™ (Abbott Vascular) with comparable tip stiffness to standard guidewires and in routine clinical use, will be used to perform the primary PCI procedure and to measure intracoronary temperature and pressure continually throughout all procedures in all patients. This will therefore limit the procedure to a simple single wire throughout strategy in most cases. In the event that the wire fails to function properly during or after the PCI procedure it may be changed for a new wire using standard interventional techniques as appropriate Patients randomised to intracoronary cooling and dilution(n=30), will receive an intracoronary infusion of room temperature 0.9% Normal Saline solution through the guiding catheter which will commence immediately prior to crossing the coronary occlusion with the guidewire. Using a 3-way tap in the procedural manifold an infusion pressure of 150mmHg above systolic blood pressure achieved with a pressure bag will be used to achieve a target intracoronary temperature of 6-8 C° below the baseline temperature. The infusion will continue until 10 minutes after the lesion is crossed and distal flow is restored, with only brief interruptions as required for the clinical procedure. A maximum volume of 750ml will be infused. The primary angioplasty procedure itself will be undertaken according to standard local practice. Patients randomised to the control group (n=30) will undergo primary PCI according to standard local practice. A complete physiological study including Fractional flow reserve (FFR), resting full-cycle ratio (RFR), coronary flow reserve (CFR), resistive reserve ratio (RRR) and index of microvascular resistance (IMR) to assess microcirculation will be measured 10 minutes after reperfusion in all patients. Patients will go on to have blood taken on the next day for the analysis of a panel of biomarkers and comparison with pre-procedure levels and in addition to have a cardiac MRI scan prior to discharge and at 6 months.

Interventions

OTHERTranscoronary cooling and dilution

Transcoronary cooling and dilution

OTHERStandard of care

Routine clinical care

Sponsors

Royal Brompton & Harefield NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Randomised placebo controlled

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical ST-elevation myocardial infarction or equivalent (e.g. new onset LBBB) * \<12 Hrs after symptom onset * Thrombolysis in myocardial infarction (TIMI) 0-1 coronary flow in a target vessel

Exclusion criteria

* History of severe asthma * Pregnancy * Severe concomitant disease or conditions with a life expectancy of less than one year.

Design outcomes

Primary

MeasureTime frameDescription
Recruitment rate1 yearPatients recruited per month
Feasibility (Number of studies where all the planned measurements have been collected / total studies)1 yearNumber of studies where all the planned measurements have been collected / total studies
Safety (Adverse events should not be significantly higher in the treatment arm compared to control, nor plausibly caused by the treatment)1 yearAdverse events should not be significantly higher in the treatment arm compared to control, nor plausibly caused by the treatment as assessed by CTCAE v5.0

Secondary

MeasureTime frameDescription
Resistive reserve ratio (RRR) 10 mins after completion of percutaneous coronary intervention and study infusion1 hourIndex of microvascular resistance rest/hyperaemia
Resting full-cycle ratio (RFR) 10 mins after completion of percutaneous coronary intervention and study infusion1 hourlowest value of distal coronary pressure/aortic pressure over the entire cardiac cycle at rest
Intracoronary temperature change1 hourIntracoronary temperature change during cooling and dilution (°C)
Infusion volume1 hourTotal volume of intracoronary saline infused (ml)
Infusion rate1 hourTotal volume of intracoronary saline infused/infusion time (ml/min)
Chest pain during study infusion1 hourWhether new chest pain arises, or chest pain increases during study infusion
ECG changes during study infusion1 hourAmelioration or worsening of the ECG anomalies during study infusion (ST elevation/depression, T wave inversion, QT prolongation)
Heart rhythm changes during study infusion1 hourAppearance or resolution of heart rhythm disturbances during study infusion (sinus tachycardia, supraventricular tachycardia, atrial tachycardia/fibrillation/flutter, ventricular tachycardia/flutter, ventricular fibrillation, sinus bradycardia, grade I, II, or III heart block, asystole.
Myocardial blush grade 10 mins after completion of percutaneous coronary intervention and study infusion1 hourAngiographic myocardial perfusion measurement based on visual assessment of the myocardium after contrast injection. Grading: 0, no myocardial blush or contrast density; 1, minimal myocardial blush or contrast density; 2, moderate myocardial blush or contrast density but less than that obtained during angiography of a contralateral or ipsilateral non-infarct-related coronary artery; and 3, normal myocardial blush or contrast density, comparable with that obtained during angiography of a contralateral or ipsilateral non-infarct-related coronary artery
Thrombolysis in Myocardial Infarction (TIMI) flow 10 mins after completion of percutaneous coronary intervention and study infusion1 hourVisual angiographic assessment of coronary flow. Grade 0 = no perfusion; grade 1 = penetration without perfusion; 2 = partial perfusion; 3 = complete perfusion
ST segment resolution 10 mins after completion of percutaneous coronary intervention and study infusion1 hourNull, partial, or complete resolution of the ST elevation
Heart Rhythm disturbance from baseline to 12 hours12 hoursAppearance or resolution of heart rhythm disturbances in the 12 hours after the procedure (sinus tachycardia, supraventricular tachycardia, atrial tachycardia/fibrillation/flutter, ventricular tachycardia/flutter, ventricular fibrillation, sinus bradycardia, grade I, II, or III heart block, asystole.
Haemodynamic compromise from baseline to 12 hours12 hoursSociety for Cardiovascular Angiography and Interventions (SCAI) class B or above
Left ventricular ejection fraction (LVEF) at 48 hours2 daysSimpson biplane (diastolic-systolic)/diastolic left ventricular volume on echocardiography
Left ventricular ejection fraction (LVEF) at 6 months6 monthsSimpson biplane (diastolic-systolic)/diastolic left ventricular volume on echocardiography
Wall motion score index (WMSI) at 48 hours48 hoursThe wall motion score index (WMSI) is an echocardiographic parameter that numerically sums the average scores for all left ventricular segments into a single parameter and then dividing by the number of segments. 1 Normal motion; 2 = hypokinesia; 3 = akinesia; 4 = dyskinesia.
Wall motion score index (WMSI) at 6 months6 monthsThe wall motion score index (WMSI) is an echocardiographic parameter that numerically sums the average scores for all left ventricular segments into a single parameter and then dividing by the number of segments. 1 Normal motion; 2 = hypokinesia; 3 = akinesia; 4 = dyskinesia.
Global longitudinal strain (GLS) at 48 hours48 hoursEchocardiographic speckle-tracking imaging that measures the systolic shortening of left ventricular segments as percentage of their diastolic length
Global longitudinal strain (GLS) at 6 months6 monthsEchocardiographic speckle-tracking imaging that measures the systolic shortening of left ventricular segments as percentage of their diastolic length
Length of stay3-5 daysDuration of hospital length of stay
Peak high-sensitivity cardiac troponin T (hs-cTnT, ng/l)1-3 daysMyocardial injury marker. Highest hs-cTnT measurement during hospital stay
N-terminal pro-brain natriuretic peptide (NT-proBNP, ng/l)1-3 daysHeart failure marker. Highest NT-proBNP measurement during hospital stay
Interleukin-1b1 dayBiomarker of inflammation during myocardial infarction
Interleukin-1 receptor antagonist1 dayBiomarker of inflammation during myocardial infarction
Interleukin-61 dayBiomarker of inflammation during myocardial infarction
Interleukin-101 dayBiomarker of inflammation during myocardial infarction
First pass microvascular obstruction extent (FP MVO)1-3 daysMeasured in 3 SAX levels to provide an index of %LV FP MVO
First pass microvascular obstruction extent (FP MVO) at 6 months6 monthsMeasured in 3 SAX levels to provide an index of %LV FP MVO
Early MVO extent (% of LV) on 1 min post-gadolinium contrast enhanced MRI, adjusted for area at-risk1-3 daysCardiac magnetic resonance-based assessment
Early MVO extent (% of LV) on 1 min post-gadolinium contrast enhanced MRI, adjusted for area at-risk, at 6 months6 monthsCardiac magnetic resonance-based assessment
Late MVO (presence / absence) on LGE1-3 daysCardiac magnetic resonance-based assessment
Late MVO (presence / absence) on LGE at 6 months6 monthsCardiac magnetic resonance-based assessment
Initial infarct size (LGE)1-3 daysMass of infarcted myocardium calculated with the full-width at half-maximum method
Infarct size (LGE) at 6 months6 monthsMass of infarcted myocardium calculated with the full-width at half-maximum method
Initial MSI (area-at-risk minus initial infarct size/area-at-risk)1-3 daysPercentage of the area at risk (calculated with the Otsu method) that was not infarcted on late gadolinium enhancement (LGE) images using infarct size from the pre-discharge (Acute MSI)
MSI (area-at-risk minus initial infarct size/area-at-risk) at 6 months6 monthsPercentage of the area at risk (calculated with the Otsu method) that was not infarcted on late gadolinium enhancement (LGE) images using infarct size from the follow-up (Final MSI) magnetic resonance imaging
Left ventricular end-diastolic volume index (LVEDVI)1-3 daysCardiac magnetic resonance-based assessment
Left ventricular end-diastolic volume index (LVEDVI) at 6 months6 monthsCardiac magnetic resonance-based assessment
Left ventricular end-systolic volume index (LVESVI)1-3 daysCardiac magnetic resonance-based assessment
Left ventricular end-systolic volume index (LVESVI) at 6 months6 monthsCardiac magnetic resonance-based assessment
Cardiac Magnetic Resonance-based Left ventricular ejection fraction (LVEF)1-3 daysCardiac magnetic resonance-based assessment
Cardiac Magnetic Resonance-based Left ventricular ejection fraction (LVEF) at 6 months6 monthsCardiac magnetic resonance-based assessment
Myocardial haemorrhage (presence/absence)1-3 daysCardiac magnetic resonance-based assessment
Myocardial haemorrhage (presence/absence) at 6 months6 monthsCardiac magnetic resonance-based assessment
Myocardial haemorrhage extent (% of LV)1-3 daysCardiac magnetic resonance-based assessment
Myocardial haemorrhage extent (% of LV) at 6 months6 monthsCardiac magnetic resonance-based assessment
Composite of all-cause mortality and hospitalization for heart failure at 6 weeks6 weeksComposite of all-cause mortality and hospitalization for heart failure at 6 weeks
Hospitalization for heart failure at 6 weeks6 weeksHospitalization for heart failure at 6 weeks
Cardiovascular mortality at 6 weeks6 weeksCardiovascular mortality at 6 weeks
All-cause mortality at 6 weeks6 weeksAll-cause mortality at 6 weeks
Hospitalization for heart failure at 6 months6 monthsHospitalization for heart failure at 6 months
Cardiovascular mortality at 6 months6 monthsCardiovascular mortality at 6 months
Index of microvascular resistance (IMR) 10 mins after completion of percutaneous coronary intervention and study infusion1 hourDistal coronary pressure during hyperaemia x mean transit time (mmHg·s)
All-cause mortality at 6 months6 monthsAll-cause mortality at 6 months
Composite of all-cause mortality and hospitalization for heart failure at 12 months12 monthsComposite of all-cause mortality and hospitalization for heart failure at 12 months
Hospitalization for heart failure at 12 months12 monthsHospitalization for heart failure at 12 months
Cardiovascular mortality at 12 months12 monthsCardiovascular mortality at 12 months
Composite of all-cause mortality and hospitalization for heart failure at 6 months6 monthsComposite of all-cause mortality and hospitalization for heart failure at 6 months
Fractional flow reserve (FFR) 10 mins after completion of percutaneous coronary intervention and study infusion1 hourDistal coronary pressure/aortic pressure during hyperaemia
Coronary flow reserve (CFR) 10 mins after completion of percutaneous coronary intervention and study infusion1 hourThermodilution-based ratio of hyperaemic coronary flow/basal flow

Countries

United Kingdom

Contacts

Primary ContactMiles C Dalby, MD
m.dalby@rbht.nhs.uk+441895 823737
Backup ContactIra Jakupovic
i.jakupovic@rbht.nhs.uk+44207 3518109

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026